Adult T-Cell Leukemia-Lymphoma Successfully Treated with 2-Chlorodeoxyadenosine

Internal Medicine

Volumn 37, Issue 4, 1998, Pages 411-413

  Uike, Naokuni ^a   Choi, Ilseung ^a   Tokoro, Akihiro ^a   Goto, Tatsuro ^a   Yufu, Yuji ^a   Kozuru, Mitsuo ^a   Tobinai, Kensei ^b  

^a NATIONAL KYUSHU CANCER CENTER   (Japan)

^b NATIONAL CANCER CENTER HOSPITAL   (Japan)

Author keywords

Partial remission; Purine nucleoside analog

Indexed keywords

CLADRIBINE; CYTOTOXIC AGENT;

AGED; ARTICLE; CANCER CHEMOTHERAPY; CASE REPORT; CONTINUOUS INFUSION; HUMAN; HUMAN CELL; INTRAVENOUS DRUG ADMINISTRATION; JAPAN; LEUKEMIA REMISSION; LYMPHADENOPATHY; MALE; T CELL LEUKEMIA; T CELL LYMPHOMA; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC AGENTS; CLADRIBINE; FOLLOW-UP STUDIES; HUMANS; INFUSIONS, INTRAVENOUS; LEUKEMIA-LYMPHOMA, T-CELL, ACUTE, HTLV-I-ASSOCIATED; MALE; NEOPLASM RECURRENCE, LOCAL;

EID: 0031744386     PISSN: 09182918     EISSN: None     Source Type: Journal    
DOI: 10.2169/internalmedicine.37.411     Document Type: Article

References (15)

1. Saven A, Carrera CJ, Carson DA, Beutler E, Piro LD. 2-chlorodeoxyadenosine: an active agent in the treatment of cutaneous T-cell lymphoma. Blood 80: 587, 1992.
2. O'Brien S, Kurzrock R, Duvic M, et al. 2-chlorodeoxyadenosine therapy in patients with T-cell lymphoproliferative disorders. Blood 84: 733, 1994.
3. Lymphoma Study Group (1984-1987). Major prognostic factors of patients with adult T-cell leukemia-lymphoma: a cooperative study. Leuk Res 15: 81, 1991.
4. Shimoyama M, Ota K, Kikuchi M, et al. Major prognostic factors of adult patients with advanced T-cell lymphoma/leukemia. J Clin Oncol 6: 1088, 1988.
5. Shimoyama M. Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma. A report from the Lymphoma Study Group (1984-87). Br J Haematol 79: 428, 1991.
6. Tanabe K, Ikegami Y, Ishida R, Andoh T. Inhibition of topoisomerase II by antitumor agents bis (2,6′-dioxopiperazine) derivatives. Cancer Res 51: 4903, 1991.
7. Ohno R, Masaoka T, Shirakawa S, et al. Treatment of adult T-cell leukemia/lymphoma with MST-16, a new oral antitumor drug and a derivative of bis (2,6-dioxopiperazine). Cancer 71: 2217, 1993.
8. Tobinai K, Ogura M, Hotta T, et al and Cladribine Study Group. Phase I study of cladribine (2-chlorodeoxyadenosine) in lymphoid malignancies. Jpn J Clin Oncol 27: 146, 1997.
9. Estey EM, Kurzrock R, Kantarjian HM, et al. Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine (2-CdA). Blood 79: 882, 1992.
10. Seto S, Carrera CJ, Kubota M, Wasson DB, Carson DA. Mechanism of deoxyadenosine and 2-chlorodeoxyadenosine toxicity to nondividing human lymphocytes. J Clin Invest 75: 377, 1985.
11. Tobinai K, Shimoyama M, Inoue S, et al and The DCF Study Group. Phase I study of YK-176 (2′-deoxycoformycin) in patients with adult T-cell leukemia-lymphoma. Jpn J Clin Oncol 22: 164, 1992.
12. Lofters W, Campbell M, Gibbs WN. Cheson BD. 2′-deoxycoformycin therapy in adult T-cell leukemia/lymphoma. Cancer 60: 2605, 1987.
13. Yamaguchi K, Yul LS, Oda T, et al. Clinical consequences of 2′-deoxycoformycin treatment in patients with refractory adult T-cell leukaemia. Leuk Res 10: 989, 1986.
14. Yoshida M, Seiki M, Yamaguchi K, Takatsuki K. Monoclonal integration of human T-cell leukemia provirus in all primary tumors of adult T-cell leukemia suggests causative role of human T-cell leukemia virus in the disease. Proc Natl Acad Sci USA 81: 2534, 1984.
15. Arima N, Daitoku Y, Ohgaki S, et al. Autocrine growth of interleukin 2-producing leukemic cells in a patient with adult T cell leukemia. Blood 68: 779, 1986.